MetaCap

ArriVent BioPharma (AVBP) vs Climb Bio (CLYM)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Climb Bio (CLYM) has outperformed ArriVent BioPharma (AVBP) over the past year, gaining 440.6% versus a loss of 48.3%. ArriVent BioPharma is the larger company by market cap ($544.1 million vs $539.8 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AVBP-48.30%CLYM+440.59%
+999%+451%-98%
Nov 21, 20251 yearNov 20, 2026
AVBP-47.40%CLYM+219.65%
+529%+221%-87%
Jan 22, 20245 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AVBP versus CLYM key metrics
MetricAVBPCLYM
Share price$10.52$9.19
Market cap$544.13M$539.80M
1-day change-6.57%-0.97%
YTD return-47.71%+129.75%
1-year return-48.30%+440.59%
5-year return—-33.21%
EPS (TTM)$-3.60$-0.81
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-166.31M$-59.85M
52-week high$35.83$18.33
52-week low$10.33$1.64
Distance from 52-week high-70.64%-49.86%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+149.05%+209.03%
Average volume1.37M1.38M
Shares outstanding51.72M58.74M
Employees7728
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • CLYM has outperformed AVBP by 488.9 percentage points over the past year.

About ArriVent BioPharma

AVBP stock →

ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company's lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment of patients with advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations, as well as Phase 1b clinical trials to treat NSCLC patients with activating EGFRm, including P-loop and-alpha-c-helix compressing (PACC) mutations, and classical EGFRm NSCLC patients.

Health Care · Biotechnology: Pharmaceutical Preparations · 77 employees

About Climb Bio

CLYM stock →

Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies to address unmet needs for patients living with immune-mediated diseases. The company's lead product candidate is the budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases.

Health Care · Biotechnology: Pharmaceutical Preparations · 28 employees

AVBP vs CLYM FAQ

Which is bigger, ArriVent BioPharma or Climb Bio?

ArriVent BioPharma (AVBP) is larger, with a market capitalization of $544.13M compared with $539.80M for Climb Bio (CLYM).

Which stock has performed better over the past year, AVBP or CLYM?

CLYM returned +440.59% over the past 12 months, compared with -48.30% for AVBP (price return, excluding dividends). Past performance does not predict future results.

Are ArriVent BioPharma and Climb Bio in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons